Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Log inTry for Free
Intellectia Logo
Log in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. RVMD
stocks logo

RVMD

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--
10 Analyst Rating
up Image0
Wall Street analysts forecast RVMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 70.63 USD with a low forecast of 57.00 USD and a high forecast of 80.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
10 Buy
0 Hold
0 Sell
Strong Buy
up Image0
Current: 36.670
sliders
Low
57.00
Averages
70.63
High
80.00
up Image0
Current: 36.670
sliders
Low
57.00
Averages
70.63
High
80.00
H.C. Wainwright
Robert Burns
Buy
downgrade
$73 -> $72
2025-05-14
Reason
H.C. Wainwright
Robert Burns
Price Target
$73 -> $72
2025-05-14
downgrade
Buy
Reason
H.C. Wainwright analyst Robert Burns lowered the firm's price target on Revolution Medicines to $72 from $73 and keeps a Buy rating on the shares following the Q1 report. The firm is factoring in higher operating expenses moving forward.
Guggenheim
Michael Schmidt
Buy
downgrade
$87 -> $80
2025-05-08
Reason
Guggenheim
Michael Schmidt
Price Target
$87 -> $80
2025-05-08
downgrade
Buy
Reason
Guggenheim analyst Michael Schmidt lowered the firm's price target on Revolution Medicines to $80 from $87 and keeps a Buy rating on the shares after the company reported Q1 results and provided a pipeline update that provided additional visibility on its potential clinical development strategy for multi-RAS inhibitor daraxonrasib and G12C-selective RAS inhibitor elironrasib in first-line non-small cell lung cancer.
Oppenheimer
Oppenheimer
Outperform
maintain
$70 -> $75
2025-05-08
Reason
Oppenheimer
Oppenheimer
Price Target
$70 -> $75
2025-05-08
maintain
Outperform
Reason
Oppenheimer raised the firm's price target on Revolution Medicines to $75 from $70 and keeps an Outperform rating on the shares. The firm notes that following the recent update describing Revolution Medicines' confidence in owning the PDAC space, the company's Q1 update, supported by a wealth of promising clinical results, further extends the potential dominance to NSCLC.
Needham
Ami Fadia
Strong Buy
Reiterates
$59
2025-04-08
Reason
Needham
Ami Fadia
Price Target
$59
2025-04-08
Reiterates
Strong Buy
Reason
Stifel
Benjamin Burnett
Strong Buy
Maintains
$78 → $64
2025-04-01
Reason
Stifel
Benjamin Burnett
Price Target
$78 → $64
2025-04-01
Maintains
Strong Buy
Reason
Stifel analyst Benjamin Burnett lowered the firm's price target on Revolution Medicines to $64 from $78 and keeps a Buy rating on the shares. Accounting the intellectual property runway, competition and historical oncology drug launches, the firm believes that the companies four opportunities combined are worth upwards of $69 per share, but it now includes a more conservative view of competition and duration-of-therapy, the analyst tells investors.
HC Wainwright & Co.
Robert Burns
Strong Buy
Maintains
$72 → $73
2025-03-03
Reason
HC Wainwright & Co.
Robert Burns
Price Target
$72 → $73
2025-03-03
Maintains
Strong Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Revolution Medicines Inc (RVMD.O) is -8.08, compared to its 5-year average forward P/E of -10.35. For a more detailed relative valuation and DCF analysis to assess Revolution Medicines Inc 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PE
-10.35
Current PE
-8.08
Overvalued PE
-5.97
Undervalued PE
-14.74

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average EV/EBITDA
-6.90
Current EV/EBITDA
-5.12
Overvalued EV/EBITDA
-3.23
Undervalued EV/EBITDA
-10.57

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
N/A
5Y Average PS
2177.31
Current PS
110.24
Overvalued PS
7814.44
Undervalued PS
-3459.81

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

RVMD News & Events

Events Timeline

(ET)
2025-06-30
08:19:59
Revolution Medicines, Summit Therapeutics team to evaluate RAS inhibitors
select
2025-06-30
08:06:08
Revolution Medicines, Summit Therapeutics enter clinical collaboration
select
2025-06-24 (ET)
2025-06-24
07:15:30
Royalty Pharma announces $2B funding arrangement with Revolution Medicines
select
Sign Up For More Events
Sign Up For More Events

News

Preview
7.5
06-30NASDAQ.COM
Revolution Medicines, Summit Therapeutics Enter Clinical Collaboration

  • Clinical Collaboration: Revolution Medicines and Summit Therapeutics have partnered to evaluate the safety and efficacy of RAS(ON) inhibitors in combination with Summit's ivonescimab across multiple solid tumor types, including non-small cell lung cancer, pancreatic cancer, and colorectal cancer.

  • Study Sponsorship and Rights: Revolution Medicines will sponsor the study while Summit Therapeutics will provide ivonescimab; both companies will retain commercial rights to their respective compounds.

Preview
7.5
06-30SeekingAlpha
Revolution Medicines and Summit Therapeutics in-pact for cancer treatments

  • Clinical Partnership Announcement: Revolution Medicines and Summit Therapeutics have formed a partnership to evaluate Revolution's RAS(ON) inhibitors alongside Summit's bispecific antibody, ivonescimab, in various solid tumor types.

  • Key Developments: The collaboration will focus on Revolution's inhibitors daraxonrasib, zoldonrasib, and elironrasib, with recent highlights including FDA Breakthrough Therapy status for daraxonrasib and a significant funding announcement for Revolution Medicines.

Preview
4.0
06-25Benzinga
Needham Reiterates Buy on Revolution Medicines, Maintains $57 Price Target

  • Real-time Intelligence: Benzinga Pro offers the fastest news alerts for traders, providing real-time intelligence to help them succeed in the stock market.

  • Community and Exclusivity: Joining Benzinga Pro connects users with over 10,000 serious traders and grants access to exclusive stories and insights from Benzinga reporters.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Revolution Medicines Inc (RVMD) stock price today?

The current price of RVMD is 36.67 USD — it has decreased -3.17 % in the last trading day.

arrow icon

What is Revolution Medicines Inc (RVMD)'s business?

Revolution Medicines, Inc. is a clinical-stage oncology company developing novel targeted therapies for RAS-addicted cancers. The Company’s research and development pipeline comprises RAS(ON) inhibitors that bind directly to RAS variants, which it refers to as RAS(ON) Inhibitors, and RAS companion inhibitors that target key nodes in the RAS pathway or associated pathways, which it refers to as RAS Companion Inhibitors. Its RAS(ON) Inhibitors are designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or in combination with RAS Companion Inhibitors or other therapeutic agents. The company’s RAS(ON) inhibitors are daraxonrasib (RMC-6236), an RAS(ON) multi-selective inhibitor; elironrasib (RMC-6291), an RAS(ON) G12C-selective inhibitor; and zoldonrasib (RMC-9805), a RAS(ON) G12D-selective inhibitor, are in clinical development. The Company’s pipeline also focuses on RAS(ON) mutant-selective inhibitors, including RMC-0708 (Q61H) and RMC-8839 (G13C).

arrow icon

What is the price predicton of RVMD Stock?

Wall Street analysts forecast RVMD stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for RVMD is 70.63 USD with a low forecast of 57.00 USD and a high forecast of 80.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Revolution Medicines Inc (RVMD)'s revenue for the last quarter?

Revolution Medicines Inc revenue for the last quarter amounts to 0.00 USD, decreased % YoY.

arrow icon

What is Revolution Medicines Inc (RVMD)'s earnings per share (EPS) for the last quarter?

Revolution Medicines Inc. EPS for the last quarter amounts to -1.13 USD, increased 61.43 % YoY.

arrow icon

What changes have occurred in the market's expectations for Revolution Medicines Inc (RVMD)'s fundamentals?

The market is revising Downward the revenue expectations for Revolution Medicines, Inc. (RVMD) for FY2025, with the revenue forecasts being adjusted by -16.67% over the past three months. During the same period, the stock price has changed by 17.80%.
arrow icon

How many employees does Revolution Medicines Inc (RVMD). have?

Revolution Medicines Inc (RVMD) has 534 emplpoyees as of July 08 2025.

arrow icon

What is Revolution Medicines Inc (RVMD) market cap?

Today RVMD has the market capitalization of 6.83B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free